Display options
Cite
Vicario G, Celio L, Bajetta E, et al. Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer. Oncol Rep. 1995;2(1):63-8doi: 10.3892/or.2.1.63.
Vicario, G., Celio, L., Bajetta, E., Zampino, M., Longhi, A., Buzzoni, R., Botti, C., Bogni, A., Bombardieri, E., Rimassa, L., & Laffranchi, A. (1995). Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer. Oncology reports, 2(1), 63-8. https://doi.org/10.3892/or.2.1.63
Vicario, G, et al. "Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer." Oncology reports vol. 2,1 (1995): 63-8. doi: https://doi.org/10.3892/or.2.1.63
Vicario G, Celio L, Bajetta E, Zampino M, Longhi A, Buzzoni R, Botti C, Bogni A, Bombardieri E, Rimassa L, Laffranchi A. Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer. Oncol Rep. 1995 Jan;2(1):63-8. doi: 10.3892/or.2.1.63. PMID: 21597690.
Copy Download .nbib Format: NLM
Share it on

Oncol Rep. 1995 Jan;2(1):63-8. doi: 10.3892/or.2.1.63.

Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer.

Oncology reports

G Vicario, L Celio, E Bajetta, M Zampino, A Longhi, R Buzzoni, C Botti, A Bogni, E Bombardieri, L Rimassa, A Laffranchi

Affiliations

  1. IST NAZL STUDIO & CURA TUMORI,DIV MED ONCOL B,VIA VENEZIAN 1,I-20133 MILAN,ITALY. IST NAZL STUDIO & CURA TUMORI,DIV NUCL MED,I-20133 MILAN,ITALY. IST NAZL STUDIO & CURA TUMORI,DIV RADIOL,I-20133 MILAN,ITALY.

PMID: 21597690 DOI: 10.3892/or.2.1.63

Abstract

Megestrol acetate (MA) is one of the most widely used progestins in the palliation of advanced breast cancer, but its optimal dose level has yet to be defined. Forty-six women with progressive advanced disease were given MA according to a monthly loading-dose-schedule (320 mg/day orally) followed by standard-dose maintenance (160 mg/day). Most of the patients had been heavily pretreated with endocrine and/or chemotherapy; all the cases were evaluable. The response rate was 20% (95% CI: 9-31%), with 9 subjects achieving PR. The median time to response was 3 months (range 2-11), the median response duration being 3 months (range 3+-12+). After a median follow-up period of 8 months (range 7-16), only 3 of the patients achieving PR are still on treatment. No increased toxicity or potentially detrimental endocrine effects were observed and all of the patients showed good compliance to treatment. Although the loading-dose schedule used in the present series proved to be feasible, it does not appear to provide any clinical advantage over standard-dose MA treatment.

Publication Types